Dysfunctional T cell metabolism in the tumor microenvironment

Cytokine and Growth Factor Reviews

Volumn 35, Issue , 2017, Pages 7-14

  Beckermann, Kathryn E ^a   Dudzinski, Stephanie O ^b   Rathmell, Jeffrey C ^c  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Glycolysis; Immunotherapy; Mitochondria; Oxidative phosphorylation; T cell

Indexed keywords

ADENOSINE A2 RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; LACTATE DEHYDROGENASE; LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOENOLPYRUVATE; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE B; S6 KINASE; TRANSCRIPTION FACTOR NFAT;

AEROBIC GLYCOLYSIS; CELL FATE; CELL METABOLISM; GENE EXPRESSION; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTE MIGRATION; MITOCHONDRION; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOUSE; NEOPLASM; OXIDATIVE PHOSPHORYLATION;

ANIMALS; GLYCOLYSIS; HUMANS; IMMUNOTHERAPY; METABOLIC NETWORKS AND PATHWAYS; MICE; MITOCHONDRIA; NEOPLASMS; OXIDATIVE PHOSPHORYLATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 85018668997     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2017.04.003     Document Type: Review

References (89)

1. Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., Mellstedt, H., Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 11 (2014), 509–524, 10.1038/nrclinonc.2014.111.
2. Galon, J., Angell, H.K., Bedognetti, D., Marincola, F.M., The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39 (2013), 11–26, 10.1016/j.immuni.2013.07.008.
3. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Spigel, D.R., Antonia, S.J., Horn, L., Drake, C.G., Pardoll, D.M., Chen, L., Sharfman, W.H., Anders, R.A., Taube, J.M., McMiller, T.L., Xu, H., Korman, A.J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G.D., Gupta, A., Wigginton, J.M., Sznol, M., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454, 10.1056/nejmoa1200690.
4. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, E.E., Felip, E., Holgado, E., Barlesi, F., Kohlhäufl, M., Arrieta, O., Burgio, M.A., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D.E., Gettinger, S.N., Rudin, C.M., Rizvi, N., Crinò, L., Blumenschein, G.R., Antonia, S.J., Dorange, C., Harbison, C.T., Graf Finckenstein, F., Brahmer, J.R., Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 1627–1639, 10.1056/NEJMoa1507643.
5. Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., Tykodi, S.S., Sosman, J.A., Procopio, G., Plimack, E.R., Castellano, D., Choueiri, T.K., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T.C., Ueda, T., Tomita, Y., Schutz, F.A., Kollmannsberger, C., Larkin, J., Ravaud, A., Simon, J.S., Xu, L.-A., Waxman, I.M., Sharma, P., Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med., 373, 2015, 150925150201006, 10.1056/NEJMoa1510665.
6. Brand, A., Singer, K., Koehl, G.E., Kolitzus, M., Schoenhammer, G., Thiel, A., Matos, C., Bruss, C., Klobuch, S., Peter, K., Kastenberger, M., Bogdan, C., Schleicher, U., Mackensen, A., Ullrich, E., Fichtner-Feigl, S., Kesselring, R., Mack, M., Ritter, U., Schmid, M., Blank, C., Dettmer, K., Oefner, P.J., Hoffmann, P., Walenta, S., Geissler, E.K., Pouyssegur, J., Villunger, A., Steven, A., Seliger, B., Schreml, S., Haferkamp, S., Kohl, E., Karrer, S., Berneburg, M., Herr, W., Mueller-Klieser, W., Renner, K., Kreutz, M., LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 24 (2016), 657–671, 10.1016/j.cmet.2016.08.011.
7. Ho, P.-C., Bihuniak, J.D., Macintyre, A.N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Micevic, G., Perales, J.C., Kleinstein, S.H., Abel, E.D., Insogna, K.L., Feske, S., Locasale, J.W., Bosenberg, M.W., Rathmell, J.C., Kaech, S.M., Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162 (2015), 1217–1228, 10.1016/j.cell.2015.08.012.
8. O'Sullivan, D., Pearce, E.L., Targeting T cell metabolism for therapy. Trends Immunol. 36 (2015), 71–80, 10.1016/j.it.2014.12.004.
9. Siska, P.J., Rathmell, J.C., T cell metabolic fitness in antitumor immunity. Trends Immunol. 36 (2015), 257–264, 10.1016/j.it.2015.02.007.
10. MacIver, N.J., Michalek, R.D., Rathmell, J.C., Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 31 (2013), 259–283, 10.1146/annurev-immunol-032712-095956.
11. Cham, C.M., Gajewski, T.F., Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J. Immunol. 174 (2005), 4670–4677 http://www.ncbi.nlm.nih.gov/pubmed/15814691 (accessed 27 February 2017).
12. Chang, C.-H., Curtis, J.D., Maggi, L.B., Faubert, B., Villarino, A.V., O'Sullivan, D., Huang, S.C.-C., van der Windt, G.J.W., Blagih, J., Qiu, J., Weber, J.D., Pearce, E.J., Jones, R.G., Pearce, E.L., Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153 (2013), 1239–1251, 10.1016/j.cell.2013.05.016.
13. Jacobs, S.R., Herman, C.E., Maciver, N.J., Wofford, J.A., Wieman, H.L., Hammen, J.J., Rathmell, J.C., Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J. Immunol. 180 (2008), 4476–4486 http://www.ncbi.nlm.nih.gov/pubmed/18354169 (accessed 18 January 2017).
14. Peng, M., Yin, N., Chhangawala, S., Xu, K., Leslie, C.S., Li, M.O., Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism. Science 354 (2016), 481–484, 10.1126/science.aaf6284.
15. Julliard, W., Fechner, J.H., Mezrich, J.D., The aryl hydrocarbon receptor meets immunology: friend or foe? A little of both. Front. Immunol., 5, 2014, 10.3389/fimmu.2014.00458.
16. Macintyre, A.N., Gerriets, V.A., Nichols, A.G., Michalek, R.D., Rudolph, M.C., Deoliveira, D., Anderson, S.M., Abel, E.D., Chen, B.J., Hale, L.P., Rathmell, J.C., The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 20 (2014), 61–72, 10.1016/j.cmet.2014.05.004.
17. + T-regulatory cell function and allograft survival. FASEB J. 29 (2015), 2315–2326, 10.1096/fj.14-268409.
18. Michalek, R.D., Gerriets, V.A., Jacobs, S.R., Macintyre, A.N., MacIver, N.J., Mason, E.F., Sullivan, S.A., Nichols, A.G., Rathmell, J.C., Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186 (2011), 3299–3303, 10.4049/jimmunol.1003613.
19. Shi, L.Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D.R., Chi, H., HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 208 (2011), 1367–1376, 10.1084/jem.20110278.
20. Frauwirth, K.A., Riley, J.L., Harris, M.H., Parry, R.V., Rathmell, J.C., Plas, D.R., Elstrom, R.L., June, C.H., Thompson, C.B., The CD28 signaling pathway regulates glucose metabolism. Immunity 16 (2002), 769–-777 http://www.ncbi.nlm.nih.gov/pubmed/12121659 (accessed 21 February 2017).
21. Parry, R.V., Chemnitz, J.M., Frauwirth, K.A., Lanfranco, A.R., Braunstein, I., Kobayashi, S.V., Linsley, P.S., Thompson, C.B., Riley, J.L., CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25 (2005), 9543–9553, 10.1128/MCB.25.21. 9543-9553.2005.
22. Patsoukis, N., Bardhan, K., Chatterjee, P., Sari, D., Liu, B., Bell, L.N., Karoly, E.D., Freeman, G.J., Petkova, V., Seth, P., Li, L., Boussiotis, V.A., PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun., 6, 2015, 6692, 10.1038/ncomms7692.
23. Mitchell, P., Moyle, J., Chemiosmotic hypothesis of oxidative phosphorylation. Nature 213 (1967), 137–139 http://www.ncbi.nlm.nih.gov/pubmed/4291593 (accessed 18 January 2017).
24. Shrestha, S., Yang, K., Guy, C., Vogel, P., Neale, G., Chi, H., Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses. Nat. Immunol. 16 (2015), 178–187, 10.1038/ni.3076.
25. Gerriets, V.A., Kishton, R.J., Nichols, A.G., Macintyre, A.N., Inoue, M., Ilkayeva, O., Winter, P.S., Liu, X., Priyadharshini, B., Slawinska, M.E., Haeberli, L., Huck, C., Turka, L.A., Wood, K.C., Hale, L.P., Smith, P.A., Schneider, M.A., MacIver, N.J., Locasale, J.W., Newgard, C.B., Shinohara, M.L., Rathmell, J.C., Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J. Clin. Invest. 125 (2015), 194–207, 10.1172/JCI76012.
26. Huynh, A., DuPage, M., Priyadharshini, B., Sage, P.T., Quiros, J., Borges, C.M., Townamchai, N., Gerriets, V.A., Rathmell, J.C., Sharpe, A.H., Bluestone, J.A., Turka, L.A., Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nat. Immunol. 16 (2015), 188–196, 10.1038/ni.3077.
27. Park, Y., Jin, H.-S., Lopez, J., Elly, C., Kim, G., Murai, M., Kronenberg, M., Liu, Y.-C., TSC1 regulates the balance between effector and regulatory T cells. J. Clin. Invest. 123 (2013), 5165–5178, 10.1172/JCI69751.
28. reg cells. J. Exp. Med. 208 (2011), 1367–1376, 10.1084/jem.20110278.
29. Dang, E.V., Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.-R., Luo, W., Zeller, K., Shimoda, L., Topalian, S.L., Semenza, G.L., Dang, C.V., Pardoll, D.M., Pan, F., Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 146 (2011), 772–784, 10.1016/j.cell.2011.07.033.
30. Waickman, A.T., Powell, J.D., mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol. Rev. 249 (2012), 43–58, 10.1111/j.1600-065X.2012.01152.x.
31. Laplante, M., Sabatini, D.M., mTOR signaling. Cold Spring Harb. Perspect. Biol., 4, 2012, a011593, 10.1101/cshperspect.a011593.
32. Delgoffe, G.M., Pollizzi, K.N., Waickman, A.T., Heikamp, E., Meyers, D.J., Horton, M.R., Xiao, B., Worley, P.F., Powell, J.D., The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12 (2011), 295–303, 10.1038/ni.2005.
33. Delgoffe, G.M., Kole, T.P., Zheng, Y., Zarek, P.E., Matthews, K.L., Xiao, B., Worley, P.F., Kozma, S.C., Powell, J.D., The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30 (2009), 832–844, 10.1016/j.immuni.2009.04.014.
34. Düvel, K., Yecies, J.L., Menon, S., Raman, P., Lipovsky, A.I., Souza, A.L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., Vander Heiden, M.G., MacKeigan, J.P., Finan, P.M., Clish, C.B., Murphy, L.O., Manning, B.D., Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39 (2010), 171–183, 10.1016/j.molcel.2010.06.022.
35. O'Neill, L.A.J., Hardie, D.G., Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 493 (2013), 346–355, 10.1038/nature11862.
36. Kishton, R.J., Barnes, C.E., Nichols, A.G., Cohen, S., Gerriets, V.A., Siska, P.J., Macintyre, A.N., Goraksha-Hicks, P., de Cubas, A.A., Liu, T., Warmoes, M.O., Abel, E.D., Yeoh, A.E.J., Gershon, T.R., Rathmell, W.K., Richards, K.L., Locasale, J.W., Rathmell, J.C., AMPK is essential to balance glycolysis and mitochondrial metabolism to control T-ALL cell stress and survival. Cell Metab. 23 (2016), 649–662, 10.1016/j.cmet.2016.03.008.
37. Michalek, R.D., Gerriets, V.A., Jacobs, S.R., Macintyre, A.N., MacIver, N.J., Mason, E.F., Sullivan, S.A., Nichols, A.G., Rathmell, J.C., Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186 (2011), 3299–3303, 10.4049/jimmunol.1003613.
38. Blagih, J., Coulombe, F., Vincent, E.E., Dupuy, F., Galicia-Vázquez, G., Yurchenko, E., Raissi, T.C., van der Windt, G.J.W., Viollet, B., Pearce, E.L., Pelletier, J., Piccirillo, C.A., Krawczyk, C.M., Divangahi, M., Jones, R.G., The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity 42 (2015), 41–54, 10.1016/j.immuni.2014.12.030.
39. Eleftheriadis, T., Pissas, G., Karioti, A., Antoniadi, G., Antoniadis, N., Liakopoulos, V., Stefanidis, I., Dichloroacetate at therapeutic concentration alters glucose metabolism and induces regulatory T-cell differentiation in alloreactive human lymphocytes. J. Basic Clin. Physiol. Pharmacol. 24 (2013), 271–276, 10.1515/jbcpp-2013-0001.
40. Berod, L., Friedrich, C., Nandan, A., Freitag, J., Hagemann, S., Harmrolfs, K., Sandouk, A., Hesse, C., Castro, C.N., Bähre, H., Tschirner, S.K., Gorinski, N., Gohmert, M., Mayer, C.T., Huehn, J., Ponimaskin, E., Abraham, W.-R., Müller, R., Lochner, M., Sparwasser, T., De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat. Med. 20 (2014), 1327–1333, 10.1038/nm.3704.
41. Zhu, J., Yamane, H., Paul, W.E., Differentiation of effector CD4 T cell populations (*). Annu. Rev. Immunol. 28 (2010), 445–489, 10.1146/annurev-immunol-030409-101212.
42. Rathmell, J.C., Vander Heiden, M.G., Harris, M.H., Frauwirth, K.A., Thompson, C.B., In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. Mol. Cell. 6 (2000), 683–692 http://www.ncbi.nlm.nih.gov/pubmed/11030347 (accessed 18 January 2017).
43. Jacobs, S.R., Michalek, R.D., Rathmell, J.C., IL-7 is essential for homeostatic control of T cell metabolism in vivo. J. Immunol. 184 (2010), 3461–3469, 10.4049/jimmunol.0902593.
44. Pitroda, S.P., Wakim, B.T., Sood, R.F., Beveridge, M.G., Beckett, M.A., MacDermed, D.M., Weichselbaum, R.R., Khodarev, N.N., STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med., 7, 2009, 68, 10.1186/1741-7015-7-68.
45. Xu, Y.S., Liang, J.J., Wang, Y., Zhao, X.-Z.J., Xu, L., Xu, Y.-Y., Zou, Q.C., Zhang, J.M., Tu, C.-E., Cui, Y.-G., Sun, W.-H., Huang, C., Yang, J.-H., Chin, Y.E., STAT3 undergoes acetylation-dependent mitochondrial translocation to regulate pyruvate metabolism. Sci. Rep., 6, 2016, 39517, 10.1038/srep39517.
46. Garama, D.J., White, C.L., Balic, J.J., Gough, D.J., Mitochondrial STAT3: Powering up a potent factor. Cytokine 87 (2016), 20–25, 10.1016/j.cyto.2016.05.019.
47. Oestreich, K.J., Read, K.A., Gilbertson, S.E., Hough, K.P., McDonald, P.W., Krishnamoorthy, V., Weinmann, A.S., Bcl-6 directly represses the gene program of the glycolysis pathway. Nat. Immunol. 15 (2014), 957–964, 10.1038/ni.2985.
48. Basu, S., Hubbard, B., Shevach, E.M., Foxp3-mediated inhibition of Akt inhibits Glut1 (glucose transporter 1) expression in human T regulatory cells. J. Leukoc. Biol. 97 (2015), 279–283, 10.1189/jlb.2AB0514-273RR.
49. Gerriets, V.A., Kishton, R.J., Johnson, M.O., Cohen, S., Siska, P.J., Nichols, A.G., Warmoes, M.O., de Cubas, A.A., MacIver, N.J., Locasale, J.W., Turka, L.A., Wells, A.D., Rathmell, J.C., Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression. Nat. Immunol. 17 (2016), 1459–1466, 10.1038/ni.3577.
50. Howie, D., Cobbold, S.P., Adams, E., Ten Bokum, A., Necula, A.S., Zhang, W., Huang, H., Roberts, D.J., Thomas, B., Hester, S.S., Vaux, D.J., Betz, A.G., Waldmann, H., Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. JCI Insight, 2, 2017, e89160, 10.1172/jci.insight.89160.
51. Jacobs, S.R., Herman, C.E., Maciver, N.J., Wofford, J.A., Wieman, H.L., Hammen, J.J., Rathmell, J.C., Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J. Immunol. 180 (2008), 4476–4486 http://www.ncbi.nlm.nih.gov/pubmed/18354169 (accessed 27 February 2017).
52. Cham, C.M., Driessens, G., O'Keefe, J.P., Gajewski, T.F., Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. Eur. J. Immunol. 38 (2008), 2438–2450, 10.1002/eji.200838289.
53. Kastirr, I., Crosti, M., Maglie, S., Paroni, M., Steckel, B., Moro, M., Pagani, M., Abrignani, S., Geginat, J., Signal strength and metabolic requirements control cytokine-induced Th17 differentiation of uncommitted human T cells. J. Immunol., 195, 2015.
54. Pavlova, N.N., Thompson, C.B., The emerging hallmarks of cancer metabolism. Cell Metab. 23 (2016), 27–47, 10.1016/j.cmet.2015.12.006.
55. Busk, M., Walenta, S., Mueller-Klieser, W., Steiniche, T., Jakobsen, S., Horsman, M.R., Overgaard, J., Inhibition of tumor lactate oxidation: consequences for the tumor microenvironment. Radiother. Oncol. 99 (2011), 404–411, 10.1016/j.radonc.2011.05.053.
56. Chang, C.-H., Qiu, J., O'Sullivan, D., Buck, M.D., Noguchi, T., Curtis, J.D., Chen, Q., Gindin, M., Gubin, M.M., van der Windt, G.J.W., Tonc, E., Schreiber, R.D., Pearce, E.J., Pearce, E.L., Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162 (2015), 1229–1241, 10.1016/j.cell.2015.08.016.
57. Nakaya, M., Xiao, Y., Zhou, X., Chang, J.-H., Chang, M., Cheng, X., Blonska, M., Lin, X., Sun, S.-C., Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity 40 (2014), 692–705, 10.1016/j.immuni.2014.04.007.
58. Sinclair, L.V., Rolf, J., Emslie, E., Shi, Y.-B., Taylor, P.M., Cantrell, D.A., Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat. Immunol. 14 (2013), 500–508, 10.1038/ni.2556.
59. Geiger, R., Rieckmann, J.C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T., Kogadeeva, M., Picotti, P., Meissner, F., Mann, M., Zamboni, N., Sallusto, F., Lanzavecchia, A., L-arginine modulates t cell metabolism and enhances survival and anti-tumor activity. Cell 167 (2016), 829–842, 10.1016/j.cell.2016.09.031 e13.
60. Wang, R., Dillon, C.P., Shi, L.Z., Milasta, S., Carter, R., Finkelstein, D., McCormick, L.L., Fitzgerald, P., Chi, H., Munger, J., Green, D.R., The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35 (2011), 871–882, 10.1016/j.immuni.2011.09.021.
61. Ravishankar, B., Liu, H., Shinde, R., Chaudhary, K., Xiao, W., Bradley, J., Koritzinsky, M., Madaio, M.P., McGaha, T.L., The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 10774–10779, 10.1073/pnas.1504276112.
62. Haas, R., Smith, J., Rocher-Ros, V., Nadkarni, S., Montero-Melendez, T., D'Acquisto, F., Bland, E.J., Bombardieri, M., Pitzalis, C., Perretti, M., Marelli-Berg, F.M., Mauro, C., Lactate regulates metabolic and pro-inflammatory circuits in control of T cell migration and effector functions. PLoS Biol., 13, 2015, e1002202, 10.1371/journal.pbio.1002202.
63. Taylor, M.W., Feng, G.S., Relationship between interferon-gamma, indoleamine 2, 3-dioxygenase, and tryptophan catabolism. FASEB J. 5 (1991), 2516–2522 http://www.ncbi.nlm.nih.gov/pubmed/1907934 (accessed 22 February 2017).
64. Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., Werner, E.R., Werner-Felmayer, G., Weiss, H.G., Göbel, G., Margreiter, R., Königsrainer, A., Fuchs, D., Amberger, A., Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-Infiltrating T cells. Clin. Cancer Res. 12 (2006), 1144–1151, 10.1158/1078-0432.CCR-05-1966.
65. Munn, D.H., Mellor, A.L., IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 37 (2016), 193–207, 10.1016/j.it.2016.01.002.
66. Murray, I.A., Patterson, A.D., Perdew, G.H., Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat. Rev. Cancer 14 (2014), 801–814, 10.1038/nrc3846.
67. Di Virgilio, F., Adinolfi, E., Extracellular purines, purinergic receptors and tumor growth. Oncogene 36 (2017), 293–303, 10.1038/onc.2016.206.
68. Wu, X.-R., He, X.-S., Chen, Y.-F., Yuan, R.-X., Zeng, Y., Lian, L., Zou, Y.-F., Lan, N., Wu, X.-J., Lan, P., High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J. Surg. Oncol. 106 (2012), 130–137, 10.1002/jso.23056.
69. Allard, B., Pommey, S., Smyth, M.J., Stagg, J., Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin. Cancer Res., 19, 2013.
70. Soliman, H.H., Jackson, E., Neuger, T., Dees, C.E., Harvey, D.R., Han, H., Ismail-Khan, R., Minton, S., Vahanian, N.N., Link, C., Sullivan, D.M., Antonia, S., A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget 5 (2014), 8136–8146, 10.18632/oncotarget.2357.
71. Siska, P.J., van der Windt, G.J.W., Kishton, R.J., Cohen, S., Eisner, W., MacIver, N.J., Kater, A.P., Weinberg, J.B., Rathmell, J.C., Suppression of Glut1 and glucose metabolism by decreased Akt/mTORC1 signaling drives T cell impairment in B cell leukemia. J. Immunol. 197 (2016), 2532–2540, 10.4049/jimmunol.1502464.
72. Saha, A., Aoyama, K., Taylor, P.A., Koehn, B.H., Veenstra, R.G., Panoskaltsis-Mortari, A., Munn, D.H., Murphy, W.J., Azuma, M., Yagita, H., Fife, B.T., Sayegh, M.H., Najafian, N., Socie, G., Ahmed, R., Freeman, G.J., Sharpe, A.H., Blazar, B.R., Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood 122 (2013), 3062–3073, 10.1182/blood-2013-05-500801.
73. Blackburn, S.D., Shin, H., Freeman, G.J., Wherry, E.J., Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 15016–15021, 10.1073/pnas.0801497105.
74. Ahmad, S., Abu-Eid, R., Shrimali, R.K., Webb, M., Verma, V., Doroodchi, A., Berrong, Z., Samara, R.N., Rodriguez, P.C., Mkrtichyan, M., Khleif, S.N., Differential PI3Kδ signaling in CD4+ T cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy. Cancer Res., 2017, 10.1158/0008-5472.CAN-16-1839 canres.1839.2016.
75. Chang, C.-H., Qiu, J., O'Sullivan, D., Buck, M.D., Noguchi, T., Curtis, J.D., Chen, Q., Gindin, M., Gubin, M.M., van der Windt, G.J.W., Tonc, E., Schreiber, R.D., Pearce, E.J., Pearce, E.L., Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162 (2015), 1229–1241, 10.1016/j.cell.2015.08.016.
76. Lazarou, M., Keeping the immune system in check: a role for mitophagy. Immunol. Cell Biol. 93 (2015), 3–10, 10.1038/icb.2014.75.
77. Buck, M.D., O'Sullivan, D., Klein Geltink, R.I., Curtis, J.D., Chang, C.-H., Sanin, D.E., Qiu, J., Kretz, O., Braas, D., van der Windt, G.J.W., Chen, Q., Huang, S.C.-C., O'Neill, C.M., Edelson, B.T., Pearce, E.J., Sesaki, H., Huber, T.B., Rambold, A.S., Pearce, E.L., Mitochondrial dynamics controls T cell fate through metabolic programming. Cell 166 (2016), 63–76, 10.1016/j.cell.2016.05.035.
78. Adams, W.C., Chen, Y.-H., Kratchmarov, R., Yen, B., Nish, S.A., Lin, W.-H.W., Rothman, N.J., Luchsinger, L.L., Klein, U., Busslinger, M., Rathmell, J.C., Snoeck, H.-W., Reiner, S.L., Anabolism-associated mitochondrial stasis driving lymphocyte differentiation over self-renewal. Cell Rep. 17 (2016), 3142–3152, 10.1016/j.celrep.2016.11.065.
79. Xu, X., Araki, K., Li, S., Han, J.-H., Ye, L., Tan, W.G., Konieczny, B.T., Bruinsma, M.W., Martinez, J., Pearce, E.L., Green, D.R., Jones, D.P., Virgin, H.W., Ahmed, R., Autophagy is essential for effector CD8(+) T cell survival and memory formation. Nat. Immunol. 15 (2014), 1152–1161, 10.1038/ni.3025.
80. Puleston, D.J., Zhang, H., Powell, T.J., Lipina, E., Sims, S., Panse, I., Watson, A.S., Cerundolo, V., Townsend, A.R., Klenerman, P., Simon, A.K., Autophagy is a critical regulator of memory CD8(+) T cell formation. Elife, 3, 2014, 10.7554/eLife.03706.
81. Schlie, K., Westerback, A., DeVorkin, L., Hughson, L.R., Brandon, J.M., MacPherson, S., Gadawski, I., Townsend, K.N., Poon, V.I., Elrick, M.A., Côté, H.C.F., Abraham, N., Wherry, E.J., Mizushima, N., Lum, J.J., Survival of effector CD8+ T cells during influenza infection is dependent on autophagy. J. Immunol. 194 (2015), 4277–4286, 10.4049/jimmunol.1402571.
82. van der Windt, G.J.W., O'Sullivan, D., Everts, B., Huang, S.C.-C., Buck, M.D., Curtis, J.D., Chang, C.-H., Smith, A.M., Ai, T., Faubert, B., Jones, R.G., Pearce, E.J., Pearce, E.L., CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 14336–14341, 10.1073/pnas.1221740110.
83. Gubser, P.M., Bantug, G.R., Razik, L., Fischer, M., Dimeloe, S., Hoenger, G., Durovic, B., Jauch, A., Hess, C., Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch. Nat. Immunol. 14 (2013), 1064–1072, 10.1038/ni.2687.
84. Bengsch, B., Johnson, A.L., Kurachi, M., Odorizzi, P.M., Pauken, K.E., Attanasio, J., Stelekati, E., McLane, L.M., Paley, M.A., Delgoffe, G.M., Wherry, E.J., Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8+ T cell exhaustion. Immunity 45 (2016), 358–373, 10.1016/j.immuni.2016.07.008.
85. Scharping, N.E., Menk, A.V., Moreci, R.S., Watkins, S.C., Ferris, R.L., Delgoffe, G.M., Whetstone, R.D., Dadey, R.E., Delgoffe, G.M., The tumor microenvironment represses t cell mitochondrial biogenesis to drive intratumoral t cell metabolic insufficiency and dysfunction. Immunity 45 (2016), 1–15, 10.1016/j.immuni.2016.07.009.
86. Jornayvaz, F.R., Shulman, G.I., Regulation of mitochondrial biogenesis. Essays Biochem. 47 (2010), 69–84, 10.1042/bse0470069.
87. Chamoto, K., Chowdhury, P.S., Kumar, A., Sonomura, K., Matsuda, F., Fagarasan, S., Honjo, T., Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc. Natl. Acad. Sci. U. S. A., 2017, 201620433, 10.1073/pnas.1620433114.
88. Fisicaro, P., Barili, V., Montanini, B., Acerbi, G., Ferracin, M., Guerrieri, F., Salerno, D., Boni, C., Massari, M., Cavallo, M.C., Grossi, G., Giuberti, T., Lampertico, P., Missale, G., Levrero, M., Ottonello, S., Ferrari, C., Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat. Med., 2017, 10.1038/nm.4275.
89. Kawalekar, O.U., O'Connor, R.S., Fraietta, J.A., Guo, L., McGettigan, S.E., Posey, A.D., Patel, P.R., Guedan, S., Scholler, J., Keith, B., Snyder, N.W., Blair, I.A., Milone, M.C., June, C.H., Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44 (2016), 380–390, 10.1016/j.immuni.2016.01.021.